Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison | Zendy

Dujana Mostafa Hamed | Zendy; Khawla Mohammad Belhoul | Zendy; Naama Abdelrahman Al Maazmi | Zendy; Farah Ghayoor | Zendy; Muneeba Moin | Zendy; Mahra Al Suwaidi | Zendy; Meerurainen | Zendy; Maryam Makki | Zendy; Mahera Abdulrahman | Zendy

Open Access

Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison

Author(s) -

Dujana Mostafa Hamed,

Khawla Mohammad Belhoul,

Naama Abdelrahman Al Maazmi,

Farah Ghayoor,

Muneeba Moin,

Mahra Al Suwaidi,

Meerurainen,

Maryam Makki,

Mahera Abdulrahman

Publication year - 2021

Publication title -

journal of infection and public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 35

eISSN - 1876-035X

pISSN - 1876-0341

DOI - 10.1016/j.jiph.2021.06.003

Subject(s) - tocilizumab , medicine , pneumonia , methylprednisolone , mechanical ventilation , intensive care unit , randomized controlled trial , randomization , oxygen therapy , medical record , mortality rate , cytokine storm , anesthesia , covid-19 , disease , infectious disease (medical specialty)

Cytokine storm is a marker of severity and severe mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia. Immunomodulatory treatments may reduce morbidity and mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research